Claims
- 1. A compound of Formula 1 wherein:R1 is hydrogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, heterocycloalkyl of 3 to 8 members, alkylcycloalkyl of 4 to 9 carbon atoms, alkylheterocycloalkyl of 4 to 9 members or (CH2)mAr or (CH2)mHet; R2 is hydrogen, alkyl of 1 to 8 carbon atoms, (CH2)nAr or (CH2)nHet; R3 is hydrogen, alkyl of 1 to 8 carbon atoms, alkylcycloalkyl of 4 to 9 carbon atoms, alkylheterocycloalkyl of 4 to 9 members, (CH2)nAr or (CH2)nHet; R4 is hydrogen or alkyl of 1 to 8 carbon atoms; R is hydrogen or alkyl of 1 to 4 carbon atoms; X is [(CH═CH)R]n, (CH2)n, or [(C≡C)R]n, CHR(CH2)n, CR2(CH2)n; a dashed line represents an optional double bond; m is an integer selected from 1 or 2; and n is an integer selected from 0, 1 or 2, or pharmaceutically acceptable salts thereof.
- 2. A compound of claim 1 wherein R1, R2, R3 and R4 are independently selected from hydrogen or alkyl.
- 3. A compound of claim 1 which is 3-(2-amino-ethyl)-1,6,7,8-tetrahydro-pyrrolo-[2,3-g]isoquinolin-5-one.
- 4. A compound of claim 1 which is 3-(2-amino-ethyl)-6-benzyl-1,6,7,8-tetrahydro-pyrrolo[2,3-g]isoquinolin-5-one.
- 5. A compound of claim 1 which is 3-(2-amino-ethyl)-6-benzylpyrrolo[2,3-g]isoquinolin-5-one.
- 6. A compound of claim 1 which is 3-(2-N-Benzylamino-ethyl)-1,6,7,8-tetrahydro-pyrrolo[2,3-g]isoquinolin-5-one.
- 7. A pharmaceutical composition comprising a compound of Formula I wherein:R1 is hydrogen, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, heterocycloalkyl of 3 to 8 members, alkylcycloalkyl of 4 to 9 carbon atoms, alkylheterocycloalkyl of 4 to 9 members or (CH2)mAr or (CH2)mHet; R2 is hydrogen, alkyl of 1 to 8 carbon atoms, (CH2)nAr or (CH2)nHet; R3 is hydrogen, alkyl of 1 to 8 carbon atoms, alkylcycloalkyl of 4 to 9 carbon atoms, alkylheterocycloalkyl of 4 to 9 members, (CH2)nAr or (CH2)nHet; R4 is hydrogen or alkyl of 1 to 8 carbon atoms; R is hydrogen or alkyl of 1 to 4 carbon atoms; X is [(CH═CH)R]n, (CH2)n, or [(C≡C)R]n, CHR(CH2)n, CR2(CH2)n; a dashed line represents an optional double bond; m is an integer selected from 1 or 2; and n is an integer selected from 0, 1 or 2, or pharmaceutically acceptable salts thereof, and a pharmaceutical carrier or excipient.
Parent Case Info
This application claims the benefit of U.S. Provisional Application No. 60/266,311, filed Feb. 4, 2000.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4260762 |
Berger |
Apr 1981 |
A |
4442291 |
Berger et al. |
Apr 1984 |
A |
Non-Patent Literature Citations (8)
Entry |
Vanhoenacker P et al. Trends in Pharmacological Sciences. (Feb. 2000). 21(2), pp. 70-77.* |
C.A. 131: 318141 XP002164267 (1999). |
C.A. 127: 273150 XP002164268 (1997). |
C.A. 127: 171786 XP002164269 (1997). |
C.A. 123: 189133 XP992164270 (1995). |
C.A. 121: 222193 XP002164271 (1994). |
C.A. 120: 1074 XP002164272 (1993). |
C.A. 130: 276228 XP002164273 (1999). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/266311 |
Feb 2000 |
US |